Lung Cancer

Panelists discuss how multistation N2 disease is no longer an absolute contraindication to surgery, with treatment decisions based on biology rather than just nodal station number, though bulky vs invasive disease characteristics matter.

Panelists discuss how concurrent chemoradiation remains standard, when possible, with sequential approaches for frail patients, and consolidation immunotherapy recommended regardless of the initial radiation approach.

The top 5 OncLive TV videos of the week cover insights in breast cancer and lung cancer.

Osimertinib plus chemotherapy resulted in a significant and improvement in OS in newly diagnosed EGFR-mutated advanced NSCLC vs osimertinib alone.

Panelists discuss how emerging therapies including DLL3-targeted ADCs, trispecific T-cell engagers, CAR T cells, and radioligand therapies represent promising approaches that may offer single-dose treatments or enhanced efficacy, though more data on durability and optimal sequencing are needed.

Panelists discuss how antibody-drug conjugates targeting B7-H3 show impressive response rates compared to historical controls, while T-cell engagers remain the priority for second-line therapy due to their demonstrated durability, though patient preferences and contraindications may influence individual treatment decisions.

Vopimetostat elicited responses and was considered tolerable in patients with MTAP-deleted solid tumors, including pancreatic and lung cancers.

The FDA granted orphan drug designation to HLX43 for thymic epithelial tumors

Percy Lee, MD, discusses different radiation modalities for patients with NSCLC, the increasing complexity of reirradiation, and the strategic use of SABR.

Panelists discuss how treatment selection for early-stage disease depends on lymph node metastasis risk, with SBRT considered for very low-risk peripheral tumors and surgery preferred when staging information is needed.

Panelists discuss how most patients with early-stage disease who would benefit from systemic therapy should receive neoadjuvant treatment, with direct surgery reserved mainly for those with medical contraindications to immunotherapy.

EIK1001 plus pembrolizumab and chemo showed a 64% ORR and manageable safety in first-line stage IV NSCLC, per phase 2 TeLuRide-005 data.

Long-term data from the ALINA trail continued to support the use of adjuvant alectinib in resected, ALK-positive, early stage non–small cell lung cancer.

Xiuning Le, MD, PhD, discusses findings from the phase 1/2 SOHO-01 trial evaluating sevabertinib monotherapy in HER2-mutant advanced NSCLC.

Pasi A. Jänne, MD, PhD, discusses OS outcomes with osimertinib with or without chemotherapy based on baseline prognostic factors in EGFR-mutant NSCLC.

Pembrolizumab before and after surgery reduced the risk of death compared with placebo for patients with early-stage non–small cell lung cancer.

Eric K. Singhi, MD, and Sandip P. Patel, MD, discuss future areas of research and unmet needs in non–small cell lung cancer.

Eric K. Singhi, MD, and Sandip P. Patel, MD, discuss key data from the 2025 World Conference on Lung Cancer.

Ivonescimab plus chemotherapy improved PFS and response rates vs tislelizumab in advanced squamous NSCLC, with a manageable safety profile.

Sacituzumab tirumotecan reduced the risk of progression or death by 51% in nonsquamous EGFR-mutated NSCLC resistant to EGFR TKIs.

Zipalertinib demonstrated preliminary efficacy and low rates of treatment-related dose reductions and discontinuations in NSCLC harboring EGFR mutations and CNS metastases and/or leptomeningeal disease.

Durvalumab in combination with chemotherapy produced outcomes consistent with prior studies in patients with advanced pleural mesothelioma.

I-DXd showed intracranial efficacy and manageable safety in ES-SCLC with brain metastases, per data from the IDeate-Lung01 study.

The SKYSCRAPER-03 trial missed the end point of a PFS benefit with tiragolumab plus atezolizumab vs durvalumab consolidation in advanced NSCLC.

Findigs from DeLLphi-304 support the use of tarlatamab as a standard of care for all patients with second-line small cell lung cancer.